{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T21:55:51Z","timestamp":1762898151676},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,9,27]],"date-time":"2005-09-27T00:00:00Z","timestamp":1127779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s00262-005-0010-0","type":"journal-article","created":{"date-parts":[[2005,9,26]],"date-time":"2005-09-26T12:12:12Z","timestamp":1127736732000},"page":"188-196","source":"Crossref","is-referenced-by-count":39,"title":["Monoclonal antibody therapy of chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"55","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,9,27]]},"reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","volume":"98","author":"M Leporrier","year":"2001","unstructured":"Leporrier M, Chevret S, Cazin B et\u2019al (2001) Randomized comparison of fludarabine, CAP, and ChOP, in 938 previously treated stage B and C-chronic lymphocytic leukemia. Blood 98:2319\u20132325","journal-title":"Blood"},{"key":"10_CR2","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Kolitz J et\u2019al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New Engl J Med 343:1750\u20131757","journal-title":"New Engl J Med"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1098\/rspl.1899.0121","volume":"66","author":"P Ehrlich","year":"1900","unstructured":"Ehrlich P (1900) The Croonian lecture: \u201con immunity with special reference to cell life\u201d. Proc Royal Soc 66:424\u2013448","journal-title":"Proc Royal Soc"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","volume":"67","author":"LM Nadler","year":"1981","unstructured":"Nadler LM, Ritz J, Hardy R et\u2019al (1981) A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 67:134\u2013140","journal-title":"J Clin Invest"},{"key":"10_CR5","first-page":"3147","volume":"40","author":"LM Nadler","year":"1980","unstructured":"Nadler LM, Stashenko P, Hardy R et\u2019al (1980) Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147\u20133154","journal-title":"Cancer Res"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","volume":"306","author":"RA Miller","year":"1982","unstructured":"Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med 306:517\u2013522","journal-title":"New Engl J Med"},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497","journal-title":"Nature"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.1984.2.8.881","volume":"2","author":"RO Dillman","year":"1984","unstructured":"Dillman RO, Shawler DL, Dillman JB, Royston I (1984) Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881\u2013891","journal-title":"J Clin Oncol"},{"key":"10_CR9","first-page":"97","volume":"7","author":"AA Hertler","year":"1988","unstructured":"Hertler AA, Schlossman DM, Borowitz MJ et\u2019al (1988) A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Resp Mod 7:97\u2013113","journal-title":"J Biol Resp Mod"},{"key":"10_CR10","first-page":"291","volume":"1","author":"AM Zimmer","year":"1988","unstructured":"Zimmer AM, Kaplan EH, Kazikiewicz JM et\u2019al (1988) Pharmacokinetics of I-131 T101 monoclonal antibody in patients with chronic lymphocytic leukemia. Antibody Immunoconjugates Radiopharm 1:291\u2013303","journal-title":"Antibody Immunoconjugates Radiopharm"},{"key":"10_CR11","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood.V67.6.1680.1680","volume":"67","author":"G Laurent","year":"1986","unstructured":"Laurent G, Pris J, Farcet J-P et\u2019al (1986) Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood 67:1680\u20131687","journal-title":"Blood"},{"key":"10_CR12","first-page":"112","volume":"28","author":"PJA Capel","year":"1985","unstructured":"Capel PJA, Preijers FWMB, Allebes WA, Haanen C (1985) Treatment of chronic lymphocytic leukaemia with monoclonal anti-idiotype antibody. Neth J Med 28:112\u2013118","journal-title":"Neth J Med"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1988.tb02485.x","volume":"70","author":"WA Allebes","year":"1988","unstructured":"Allebes WA, Preijers FWMB, Haanen C, Capel PJA (1988) The development of non-responsiveness to immunotherapy with monoclonal anti-idiotypic antibodies in a patient with B-CLL. Br J Haematol 70:295\u2013300","journal-title":"Br J Haematol"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1399-0039.1990.tb01767.x","volume":"35","author":"G Hale","year":"1990","unstructured":"Hale G, Xia M-Q, Tighe HP et\u2019al (1990) The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:118\u2013127","journal-title":"Tissue Antigens"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De martinis M, Matutes E et\u2019al (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H. Leuk Res 22:185\u2013191","journal-title":"Leuk Res"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood.V73.6.1431.1431","volume":"73","author":"MJS Dyer","year":"1989","unstructured":"Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431\u20131439","journal-title":"Blood"},{"key":"10_CR17","first-page":"52","volume":"26","author":"MJ Dyer","year":"1999","unstructured":"Dyer MJ (1999) The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26:52\u201357","journal-title":"Semin Oncol"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10428199009053522","volume":"2","author":"MJ Dyer","year":"1990","unstructured":"Dyer MJ, Hale G, Marcus RE, Waldmann H (1990) Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies. Leuk Lymph 2:179\u2013190","journal-title":"Leuk Lymph"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A \u00d6sterborg","year":"1997","unstructured":"\u00d6sterborg A, Dyer MJS, Bunjes D et\u2019al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15:1567\u20131574","journal-title":"J Clin Oncol"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x","volume":"96","author":"AL Bowen","year":"1997","unstructured":"Bowen AL, Zomas A, Emmett E et\u2019al (1997) Subcutaneous CAMPATH-1H in fludarabine-resistant\/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96:617\u2013619","journal-title":"Br J Haematol"},{"key":"10_CR21","first-page":"529a","volume":"90","author":"AC Rawstron","year":"1997","unstructured":"Rawstron AC, Davies FE, Evans P et\u2019al (1997) CAMPATH1H therapy for patients with refractory chronic lymphocytic leukemia (CLL). Blood 90:529a (abstr 2356)","journal-title":"Blood"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V et\u2019al (2002) Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554\u20133561","journal-title":"Blood"},{"key":"10_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","volume":"93","author":"A \u00d6sterborg","year":"1996","unstructured":"\u00d6sterborg A, Fassas AS, Anagnostopoulos A et\u2019al (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93:151\u2013153","journal-title":"Br J Haematol"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/10428190290021597","volume":"43","author":"SL McCune","year":"2002","unstructured":"McCune SL, Gockerman JP, Moore JO et\u2019al (2002) Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymph 43:1007\u20131011","journal-title":"Leuk Lymph"},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bj\u00f6rkholm M et\u2019al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (CAMPATH-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768\u2013773","journal-title":"Blood"},{"key":"10_CR26","first-page":"365a","volume":"98","author":"KR Rai","year":"2001","unstructured":"Rai KR, Coutr\u00e9 S, Rizzieri D et\u2019al (2001) Efficacy and safety of alemtuzumab (CAMPATH-1H) in refractory B-CLL patients treated on a compassionate basis. Blood 98:365a (abstr 1538)","journal-title":"Blood"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","volume":"347","author":"S Stilgenbauer","year":"2002","unstructured":"Stilgenbauer S, D\u00f6hner H (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 mutation and resistance to chemotherapy. New Engl J Med 347:452\u2013452","journal-title":"New Engl J Med"},{"key":"10_CR28","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/cncr.0680","volume":"94","author":"JG Perkins","year":"2002","unstructured":"Perkins JG, Flynn JM, Howard RS, Byrd JC (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 94:2033\u20132039","journal-title":"Cancer"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","volume":"104","author":"G Hale","year":"2004","unstructured":"Hale G, Rebello P, Breitman LR et\u2019al (2004) Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104:948\u2013955","journal-title":"Blood"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"140a","DOI":"10.1182\/blood.V104.11.478.478","volume":"104","author":"S Stilgenbauer","year":"2004","unstructured":"Stilgenbauer S, Winkler D, Kr\u00f6ber A et\u2019al (2004) Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: Interim analysis of the CLL2h study of the German CLL Study Group (GCLLSG). Blood 104:140a (abstr#478)","journal-title":"Blood"},{"key":"10_CR31","first-page":"676","volume":"102","author":"KR Rai","year":"2003","unstructured":"Rai KR, Byrd JC, Peterson B et\u2019al (2003) Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901. Blood 102:676\u2013677a (abstr#2506)","journal-title":"Blood"},{"key":"10_CR32","first-page":"205a","volume":"100","author":"KR Rai","year":"2002","unstructured":"Rai KR, Byrd JC, Peterson B, Larson RA (2002) A phase II trial of fludarabine followed by alemtuzumab (CAMPATH-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901. Blood 100:205a (abstr 772)","journal-title":"Blood"},{"key":"10_CR33","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","volume":"99","author":"B Kennedy","year":"2002","unstructured":"Kennedy B, Rawstron A, Carter C et\u2019al (2002) CAMPATH-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99:2245\u20132247","journal-title":"Blood"},{"key":"10_CR34","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V104.11.2517.2517","volume":"104","author":"T Elter","year":"2004","unstructured":"Elter T, Bochmann P, Schulz H et\u2019al (2004) FluCam - a new, 4-weekly combination of fludarabine and alemtuzumab for patients with relapsed chronic lymphocytic leukemia. Blood 104:690a (abstr 2517)","journal-title":"Blood"},{"key":"10_CR35","doi-asserted-by":"crossref","first-page":"140a","DOI":"10.1182\/blood.V104.11.479.479","volume":"104","author":"M Montillo","year":"2004","unstructured":"Montillo M, Tedeschi A, Rossi V et\u2019al (2004) Alemtuzumab as consolidation after a response to fludarabine is effective to purge residual disease in patients with chronic lymphocytic leukemia. Blood 104:140a (abstr#479)","journal-title":"Blood"},{"key":"10_CR36","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","volume":"98","author":"SM O\u02019Brien","year":"2003","unstructured":"O\u02019Brien SM, Kantarjian HM, Thomas DA et\u2019al (2003) Alemtuzumab as treatment for residual disease after chemotherapy on patients with chronic lymphocytic leukemia. Cancer 98:2657\u20132663","journal-title":"Cancer"},{"key":"10_CR37","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","volume":"18","author":"C-M Wendtner","year":"2004","unstructured":"Wendtner C-M, Ritgen M, Schweighofer CD et\u2019al (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group. Leukemia 18:1093\u20131101","journal-title":"Leukemia"},{"key":"10_CR38","doi-asserted-by":"crossref","unstructured":"Moreton P, Kennedy B, Lucas G et\u2019al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol epub, Feb 28","DOI":"10.1200\/JCO.2005.04.021"},{"key":"10_CR39","doi-asserted-by":"crossref","first-page":"101a","DOI":"10.1182\/blood.V104.11.340.340","volume":"104","author":"W Wierda","year":"2004","unstructured":"Wierda W, Faderl S, O\u02019Brien S et\u2019al (2004) Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL. Blood 104:101a (abstr#340)","journal-title":"Blood"},{"key":"10_CR40","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW et\u2019al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278\u20133281","journal-title":"Blood"},{"key":"10_CR41","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","volume":"85","author":"H D\u00f6hner","year":"1995","unstructured":"D\u00f6hner H, Fischer K, Bentz M et\u2019al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580\u20131589","journal-title":"Blood"},{"key":"10_CR42","doi-asserted-by":"crossref","unstructured":"Lin TS, Flinn IW, Modali R et\u2019al (2004) FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia. Blood (in press)","DOI":"10.1182\/blood-2004-02-0651"},{"key":"10_CR43","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2002-10-3270","volume":"103","author":"AC Rawstron","year":"2004","unstructured":"Rawstron AC, Kennedy B, Moreton P et\u2019al (2004) Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 103:2027\u20132031","journal-title":"Blood"},{"key":"10_CR44","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK et\u2019al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825\u20132833","journal-title":"J Clin Oncol"},{"key":"10_CR45","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J et\u2019al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting\u2014Airlie House, Virginia. J Clin Oncol 17:3835\u20133849","journal-title":"J Clin Oncol"},{"key":"10_CR46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","volume":"62","author":"DT Nguyen","year":"1999","unstructured":"Nguyen DT, Amess JA, Doughty H et\u2019al (1999) IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin\u02019s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 62:76\u201382","journal-title":"Eur J Haematol"},{"key":"10_CR47","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA et\u2019al (1997) IDEC-C2B8 (Rituximab) anti-CD20- monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u02019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"10_CR48","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-Lopez AJ et\u2019al (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u02019s lymphoma. Ann Oncol 10:655\u2013661","journal-title":"Ann Oncol"},{"key":"10_CR49","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O et\u2019al (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217\u20132224","journal-title":"Blood"},{"key":"10_CR50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZ, Cunningham D et\u2019al (2000) European phase II study of rituximab (Chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317\u2013324","journal-title":"J Clin Oncol"},{"key":"10_CR51","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O\u02019Brien","year":"2001","unstructured":"O\u02019Brien SM, Kantarjian H, Thomas DA et\u2019al (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165\u20132170","journal-title":"J Clin Oncol"},{"key":"10_CR52","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"JC Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS et\u2019al (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153\u20132164","journal-title":"J Clin Oncol"},{"key":"10_CR53","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","volume":"98","author":"D Huhn","year":"2001","unstructured":"Huhn D, von Schilling C, Wilhelm M et\u2019al (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326\u20131331","journal-title":"Blood"},{"key":"10_CR54","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","volume":"21","author":"JD Hainsworth","year":"2003","unstructured":"Hainsworth JD, Lichty S, Barton JH et\u2019al (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746\u20131751","journal-title":"J Clin Oncol"},{"key":"10_CR55","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Lichty S, Burris HA III et\u2019al (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u02019s lymphoma. J Clin Oncol 20:4261\u20134267","journal-title":"J Clin Oncol"},{"key":"10_CR56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","volume":"101","author":"JC Byrd","year":"2003","unstructured":"Byrd JC, Peterson B, Morrison VA et\u2019al (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6\u201314","journal-title":"Blood"},{"key":"10_CR57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","volume":"105","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Rai K, Peterson BL et\u2019al (2005) The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49\u201353","journal-title":"Blood"},{"key":"10_CR58","unstructured":"Keating MJ, O\u02019Brien S, Albitar M et\u2019al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy for chronic lymphocytic leukemia. J Clin Oncol epub ahead of print, March 14"},{"key":"10_CR59","doi-asserted-by":"crossref","unstructured":"Wierda W, O\u02019Brien S, Wen S et\u2019al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol epub ahead of print, March 14","DOI":"10.1200\/JCO.2005.12.516"},{"key":"10_CR60","first-page":"219a","volume":"98","author":"HH Ghazal","year":"2001","unstructured":"Ghazal HH (2001) Successful treatment of pure red cell aplasia (PRA) with rituxan in patients with CLL. Blood 98:219a (abstr 914)","journal-title":"Blood"},{"key":"10_CR61","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V100.6.2260","volume":"100","author":"UP Hegde","year":"2002","unstructured":"Hegde UP, Wilson WH, White T, Cheson BD (2002) Rituximab treatment of refractory fludarabine -associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 100:2260\u20132262","journal-title":"Blood"},{"key":"10_CR62","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/10428190412331286096","volume":"45","author":"C Nabhan","year":"2004","unstructured":"Nabhan C, Patton D, Gordon L et\u2019al (2004) A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and\/or refractory chronic lymphocytic leukemia. Leuk Lymph 45:2269\u20132273","journal-title":"Leuk Lymph"},{"key":"10_CR63","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","volume":"101","author":"S Faderl","year":"2003","unstructured":"Faderl S, Thomas DA, O\u02019Brien S et\u2019al (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413\u20133415","journal-title":"Blood"},{"key":"10_CR64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1006341717398","volume":"18","author":"RO Dillman","year":"1999","unstructured":"Dillman RO (1999) Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18:465\u2013471","journal-title":"Cancer Metastasis Rev"},{"key":"10_CR65","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","volume":"17","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, Waselenko JK, Maneatis T et\u2019al (1999) Rituximab therapy in hematologic malignancy patients with circulating tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791\u2013795","journal-title":"J Clin Oncol"},{"key":"10_CR66","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1200\/JCO.1998.16.7.2313","volume":"16","author":"BD Cheson","year":"1998","unstructured":"Cheson BD, Frame JN, Vena D et\u2019al (1998) Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16:2313\u20132320","journal-title":"J Clin Oncol"},{"key":"10_CR67","first-page":"384a","volume":"100","author":"KR Rai","year":"2002","unstructured":"Rai KR, O\u02019Brien S, Cunningham C et\u2019al (2002) Genasense (Bcl-2 antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: phase I and II results. Blood 100:384a (abstr 1490)","journal-title":"Blood"},{"key":"10_CR68","unstructured":"Rai KR, Moore JO, Boyd TE et\u2019al (2004) Phase 3 randomized trial of fludarabine\/cyclophosphamide chemotherapy with or without oblimerson sodium (Bcl-2 antisense; Genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood:abstr 338"},{"key":"10_CR69","doi-asserted-by":"crossref","unstructured":"Chanan-Khan AA, Mavromatis B, Rai KR et\u2019al (2004) A pilot study of Genasense (Oblimersen sodium, Bcl-2 antisense oligonucleotide), fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemia. Blood 104:abstr 4827","DOI":"10.1182\/blood.V104.11.4827.4827"},{"key":"10_CR70","first-page":"367a","volume":"98","author":"N Pathan","year":"2001","unstructured":"Pathan N, Hariharan K, Hopkins M et\u2019al (2001) Induction of apoptosis by IDEC-152 (anti-CD23) in lymphoma cells. Blood 98:367a (abstr 1545)","journal-title":"Blood"},{"key":"10_CR71","unstructured":"Byrd J, O\u02019Brien S, Flinn I et\u2019al (2003) Interim results from a phase I study of lumiliximab (IDEC-152, anti-CD23 antibody) therapy for relapsed or refractory CLL. Blood 102:abstr 248"},{"key":"10_CR72","doi-asserted-by":"crossref","first-page":"258265","DOI":"10.1038\/sj.leu.2400556","volume":"11","author":"A K\u00f6nig","year":"1997","unstructured":"K\u00f6nig A, Menzel T, Lynen S et\u2019al (1997) Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11:258265","journal-title":"Leukemia"},{"key":"10_CR73","first-page":"9a","volume":"21","author":"VK Langmuir","year":"2002","unstructured":"Langmuir VK, Cobleigh MA, Herbst RS et\u2019al (2002) Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Amer Soc Clin Oncol 21:9a (abstr 32)","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"10_CR74","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1015626410273","volume":"20","author":"D Figg","year":"2002","unstructured":"Figg D, Fruger EA, Price DK (2002) Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Inv New Drugs 20:183\u2013194","journal-title":"Inv New Drugs"},{"key":"10_CR75","first-page":"198a","volume":"100","author":"JE Karp","year":"2002","unstructured":"Karp JE, Gojo I, Gocke CD et\u2019al (2002) Timed sequential therapy (TST) of relapsed and refractory adult acute myelogenous leukemia (AML) with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab. Blood 100:198a (abstr 744)","journal-title":"Blood"},{"key":"10_CR76","doi-asserted-by":"crossref","unstructured":"Cheson BD (2003) Radioimmunotherapy of non-Hodgkin\u02019s lymphomas. Blood 101(in press) (Jan 15)","DOI":"10.1182\/blood-2002-06-1793"},{"key":"10_CR77","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2002.02.126","volume":"20","author":"RO Dillman","year":"2002","unstructured":"Dillman RO (2002) Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 20:3545\u20133547","journal-title":"J Clin Oncol"},{"key":"10_CR78","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/1097-0142(19940301)73:5<1425::AID-CNCR2820730517>3.0.CO;2-D","volume":"73","author":"GJ DeNardo","year":"1993","unstructured":"DeNardo GJ, Lewis JP, DeNardo SJ, O\u02019Grady LF (1993) Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73:1425\u20131432","journal-title":"Cancer"},{"key":"10_CR79","first-page":"830","volume":"47","author":"AL Epstein","year":"1987","unstructured":"Epstein AL, Marder RJ, Winter JN et\u2019al (1987) Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47:830\u2013840","journal-title":"Cancer Res"},{"key":"10_CR80","first-page":"295a","volume":"76","author":"JP Lewis","year":"1990","unstructured":"Lewis JP, DeNardo GL, DeNardo SJ, O\u02019Grady LF (1990) Impact of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia (CLL). Blood 76:295a (abstr 1171)","journal-title":"Blood"},{"key":"10_CR81","first-page":"17","volume":"1","author":"SJ DeNardo","year":"1988","unstructured":"DeNardo SJ, DeNardo GL, O\u02019Grady LF et\u2019al. (1988) Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconjugates Radiopharm 1:17\u201333","journal-title":"Antibody Immunoconjugates Radiopharm"},{"key":"10_CR82","first-page":"1014s","volume":"50","author":"GL DeNardo","year":"1990","unstructured":"DeNardo GL, DeNardo SJ, O\u02019Grady LF et\u2019al (1990) Fractionated radioimmunotherapy of B-cell malignancies with 131 I-Lym-1. Cancer Res 50:1014s\u20131016s","journal-title":"Cancer Res"},{"key":"10_CR83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hon.2900070207","volume":"7","author":"E Hu","year":"1989","unstructured":"Hu E, Epstein AL, Naeve GS et\u2019al (1989) A phase Ia clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7:155\u2013166","journal-title":"Hematol Oncol"},{"key":"10_CR84","first-page":"abstr 386","volume":"94","author":"MS Kaminski","year":"1999","unstructured":"Kaminski MS, Press OW, Lister TA et\u2019al (1999) Iodine I131 tositumomab for patients with small lymphocytic lymphoma (SLL): overall clinical trial experience. Blood 94:abstr 386","journal-title":"Blood"},{"key":"10_CR85","doi-asserted-by":"crossref","unstructured":"McGreivy JS, Marshall J, Cheson BD et\u2019al (2005) Initial results from ongoing Phase I trials of a novel pan bcl-2 family small molecule inhibitor. Proc ASCO (in press)","DOI":"10.1200\/jco.2005.23.16_suppl.3180"},{"key":"10_CR86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.V100.1.167","volume":"100","author":"AM Krackhardt","year":"2002","unstructured":"Krackhardt AM, Harig S, Witzens M et\u2019al (2002) T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 100:167\u2013173","journal-title":"Blood"},{"key":"10_CR87","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2004.05070.x","volume":"126","author":"AP Kater","year":"2004","unstructured":"Kater AP, Remmerswaal EBM, Nolte MA et\u2019al (2004) Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br J Haematol 126:512\u2013516","journal-title":"Br J Haematol"},{"key":"10_CR88","first-page":"1656","volume":"9","author":"E Gitelson","year":"2003","unstructured":"Gitelson E, Hammond C, Mena J et\u2019al (2003) Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 9:1656\u20131665","journal-title":"Clin Cancer Res"},{"key":"10_CR89","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2003-06-2097","volume":"103","author":"MR M\u00fcller","year":"2004","unstructured":"M\u00fcller MR, Tsakou G, Gr\u00fcnebach F et\u2019al (2004) Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 103:1763\u20131769","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-005-0010-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0010-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T19:27:36Z","timestamp":1683228456000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-005-0010-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,27]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s00262-005-0010-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,27]]}}}